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Objectives: Osteoarthritis (OA) is the most common and costly bone and joint 
disease in the elderly. Recently, viscosupplementation, an intra-articular injection 
of artificial joint fluid in order to restore rheological properties affecting lubrica-
tion and shock absorption, has introduced as an alternative conservative treat-
ment. To assess the effectiveness and cost-effectiveness of Hylan G-F 20 (Hylan) as 
a substitute for existing treatments for pain due to OA of the knee, other viscosup-
plementation devices, and/or as an adjunct to conventional therapy. MethOds: A 
Markov microsimulation model was developed to define a treatment pathway for 
OA of the knee, illustrate the current costs of treating patients with the condition, 
and demonstrate the potential savings associated with introduction of Hylan. 
A hypothetical cohort of patients categorized as having 2-3 or 4 degree of OA of 
the knee was followed over a 30-month time period. Results: When compar-
ing intra-articular administration of Hylan, the use of NSAIDs and intra-articular 
administration of corticosteroids (GCS), rirost costs compared with the strategy 
of NSAIDs amounted to $192 rate per 1 patient. This increase in efficiency of 20% 
in favor of Hylan. Accordingly, the ratio ICER was $979 per patient, which is much 
below the threshold of “society’s willingness to pay.” Markov cycle for patients 
with OA of the knee of 4 degrees showed that use of Hylan is more effective in the 
end point of modeling the effectiveness of this strategy was 12% (compared to 
0% in the policies of NSAIDs and corticosteroids). We calculated the total cost of 
the budget in the application of NSAIDs, GCS, and Hylan, after calculations found 
that the use of Gilan can save significant budget funds - up to $954582 (for 1,000 
patients). cOnclusiOns: Hylan may delay the need for joint replacement in 
patients with OA of 4 degrees, suggest its use is justified from a clinical and eco-
nomic standpoint as compared to the consideration of other treatment strategies.
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Objectives: Failed back surgery syndrome (FBSS) represents one main cause 
of chronic neuropathic or mixed pain and functional disability. Results from 
previous clinical trials and from the PRECISE naturalistic study [Zucco et al, 
Neuromodulation, 2015] show that Spinal Cord Stimulation (SCS) provides pain 
relief and improves patients’ health. Our current aim is to understand the rela-
tionship between pain intensity, functional disability, and overall Health-Related 
Quality-of-life (HRQoL). MethOds: At recruitment (before SCS) and every 6 
months for 2 years after SCS a battery of questionnaires/tests were completed: 
EQ-5D-3L and SF-36 for HRQoL, the Numerical Rating Scale (NRS) to measure pain 
intensity, and the Oswestry Disability Index (ODI) to measure disability/functional 
capability. Statistical tests were conducted to compare the HRQoL levels (using the 
EQ-5D utility index, the EQ-VAS, the SF-36 Physical Component Summary (PCS) 
and Mental Component Summary (MCS) index), NRS and ODI at baseline with 
those measured during the observational period. Multilevel regression analyses 
were conducted to investigate the association between the HRQOL indexes and 
the NRS and ODI indexes, on adjusting for: age, gender, previous surgery, educa-
tion, baseline level of the dependent variable, and time of assessment. Results: 
Eighty patients (40% male, mean age= 58 years) participated. Significant improve-
ments (p< 0.001) in pain intensity, functional capability and HRQoL were reached 
after 6 months from SCS and maintained or further improved until the end of 
the observational period. According to the regression models, every HRQoL index 
was significantly associated (p< 0.001) with both the NRS and the ODI indexes 
at any time of assessment. cOnclusiOns: Our results suggest that in a 2-year 
observational period, SCS+CMM treatment reduces significantly pain intensity and 
functional disability in patients with FBSS, with significant repercussions on their 
general HRQOL. Furthermore, our results suggest the HRQoL instruments used in 
this study are valid to assess overall patients’ health and treatment outcomes.
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Objectives: Effective but expensive (approximately € 14,000 per year) tumor 
necrosis factor inhibiting drugs (TNFi) are used for the treatment of several chronic 
inflammatory diseases including rheumatoid arthritis (RA). A proven dose reduc-
tion strategy in RA patients could result in substantial cost savings. It may however 
also lead to a loss of quality of life as a result of flares induced by dose reduction 
attempts. If this loss is compensated with large cost saving, we might still consider 
the intervention cost-effective. MethOds: a pre-planned cost-effectiveness analy-
sis of the DRESS study, a randomised controlled, non-inferiority trial comparing a 
disease activity guided dose optimisation strategy with usual care in patients with 
RA and low disease activity using TNFi. Total health care costs were measured and 
quality adjusted life years (QALY) were based on EQ5d utilities. Decremental cost-
effectiveness ratio and incremental net monetary benefit (iNMB) were determined. 
of the Psoriatic Arthritis Response Criteria, Health Assessment Questionnaire 
and Psoriasis Area and Severity Index data, synthesized from published clini-
cal trials via a Bayesian network meta-analysis. Following a payer perspective, 
direct costs relating to drug acquisition, administration, monitoring and overall 
patient management were considered (2015). Results: All anti-TNF therapies 
yielded greater improvements in the aforementioned efficacy outcomes and in 
terms of quality-adjusted life years (QALYs) compared to SoC. The incremental 
cost per QALY gained of CZP relative to SoC was € 16,539 and € 20,714 at 12- and 
24-week response assessment period respectively, which is below the established 
willingness-to-pay threshold of € 34,000. Between the anti-TNFs, efficacy differ-
ences did not reach statistical significance. In terms of the mean lifetime patient 
cost, it ranged from € 61,469 for CZP to € 86,632 for infliximab, assuming a 12-week 
response assessment period. Similarly, at the alternative assessment period sce-
nario, it ranged from € 66,401 and € 67,499 for golimumab and CZP respectively, to 
€ 83,483 for infliximab. cOnclusiOns: CZP was found to be cost-effective relative 
to SoC and as effective in terms of efficacy and less costly, i.e. dominant, compared 
to most other licensed anti-TNF agents in Greece.
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Objectives: A Telerehabilitation service following Total Knee Replacement (TKR) 
has been shown to be not inferior to standard rehabilitation (SR) in recovering the 
active knee flexion range of motion (ROM) in patients who had not complication 
related to TKR surgery. However, little is known about its cost-effectiveness. The 
objective of this economic evaluation was to assess cost-effectiveness of telereha-
bilitation versus SR. MethOds: A Markov model was employed to simulate the 
natural progression of TKR, assuming telerehabilitation does not influence this. 
The revision risk was calculated from patient-level data (multicentre KAT trial) 
employing a parametric model including established prognostic factors. The others 
state-transition probabilities and treatments effects were obtained from published 
literature. Rehabilitation and transportation costs were assessed adopting Ita-
NHS perspective employing Italian tariffs. The patients without complications 
followed the TR-SR programme receiving half of the sessions in SR and half in 
telerehabilitation regime. Patients with any complication followed the SR receiv-
ing face-to-face sessions. Results were adjusted applying an annual discount rate 
of 3% and half-cycle correction. Probabilistic sensitivity analysis (PSA) described 
the parameters uncertainty. Results: A cohort of 1000 patients with the features 
of KAT trial population (70 years old, 44% male and 19% had any complication 
related to the surgery) were first assigned to SR then to TR -SR. The mean (SE) 
lifetime healthcare cost in SR arm were € 1,033.81 (€ 21.97) and € 818.44 (€ 13.82) for 
telerehabilitation (mean±95%CI difference -215.33±€ 10.64). Mean (SE) ROM was 
16.68 (0.04) in SR programme and 18.84 (0.04) in telerehabilitation programme 
(mean±95%CI difference 2.16±0.09). The probability that telerehabilitation is cost-
saving (WTP:€ 0) is 92%. cOnclusiOns: Adopting the healthcare provider per-
spective, TR-SR seems cost-effective when compared to a SR programme. Further 
sensitivity analyses are required to relax the model assumptions and to assess 
the robustness of the model.
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Objectives: This study aims to evaluate the cost-effectiveness of Tocilizumab-
based-regimen and other four biologic-based-regimens for the treatments of 
DMARD-IR rheumatoid arthritis patients in China. MethOds: A network meta-
analysis (NMA) was performed to combine and compare ACR response rates across 
all relevant RCT evidences. The real-world treatment fees, including drugs, monitor-
ing and administration fees, were collected through expert interviews in Beijing, 
Shanghai, Guangzhou and Chengdu city. All Patient-Assistant-Programs were con-
sidered in drug-cost calculation. The cost-effectiveness analysis was conducted to 
evaluate average costs per ACR20/50/70 response among five regimens. Results: 
The NMA analysis included 28 eligible RCTs. The results indicated that ACR20/50/70 
response rates of Tocilizumab-based-regimen were 74%, 56% and 28% respectively. 
While the ACR20/50/70 response rates of other four regimens (Adalimumab, 
Infliximab, Etanercept and Etanercept-NCB (Non-Comparable-Biologics)) were 77%, 
55% and 19% respectively. The total treatment fees of these five regimens within 
48-weeks were calculated to be RMB 87,384, RMB 113,162, RMB 82,386, RMB 154,894 
and RMB 93,582. The cost-effectiveness results demonstrated that, compared 
with other four regimens, Tocilizumab-regimen cost the average of RMB 312,087 
(USD50,336) to achieve an ACR70 response. It cost RMB 118,087 (USD19,046) per 
ACR20 response and RMB 156,044 (USD25,168) per ACR50 response, which were 
comparable with Infliximab-regimen, but less than others. Tocilizumab could save 
costs ranged from RMB 3,449 (USD556) to RMB 503,147 (USD81,152) in order to fully 
achieve ACR20/50/70 response rates compared with other regimens. cOnclusiOns: 
The study demonstrated that, compared with other available biologicals in China, 
Tocilizumab-regimen was the most cost-effective to achieve ultimate ACR70 
response for DMARD-IR rheumatoid arthritis patients. It also suggested that it had 
similar cost-effectiveness results to Infliximab to achieve ACR20/50 responses.
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